Taeyoen Lim

Sep 10, 2024 | bioprocessonline.com | Seulki Lee |Jiyeon Lee |Taeyoen Lim |Jaewoon Kim

Article | September 10, 2024 By Seulki Lee, Jiyeon Lee, Taeyoen Lim, and Jaewoon Kim, Samsung Biologics Charge variants, resulting from post-translational modifications or chemical degradation, are a significant concern in monoclonal antibody (mAb) development and manufacturing. Shifts in isoelectric point (PI) values can lead to charge heterogeneity, impacting drug efficacy and safety. Controlling charge variants is crucial for regulatory approval and clinical success.

Sep 10, 2024 | outsourcedpharma.com | Seulki Lee |Jiyeon Lee |Taeyoen Lim |Jaewoon Kim |Louis Garguilo

Article | September 10, 2024 By Seulki Lee, Jiyeon Lee, Taeyoen Lim, and Jaewoon Kim, Samsung Biologics Charge variants, resulting from post-translational modifications or chemical degradation, are a significant concern in monoclonal antibody (mAb) development and manufacturing. Shifts in isoelectric point (PI) values can lead to charge heterogeneity, impacting drug efficacy and safety. Controlling charge variants is crucial for regulatory approval and clinical success.

Sep 10, 2024 | pharmaceuticalonline.com | Seulki Lee |Jiyeon Lee |Taeyoen Lim |Jaewoon Kim

Article | September 10, 2024 By Seulki Lee, Jiyeon Lee, Taeyoen Lim, and Jaewoon Kim, Samsung Biologics Charge variants, resulting from post-translational modifications or chemical degradation, are a significant concern in monoclonal antibody (mAb) development and manufacturing. Shifts in isoelectric point (PI) values can lead to charge heterogeneity, impacting drug efficacy and safety. Controlling charge variants is crucial for regulatory approval and clinical success.